Eli Lilly Continues Crusade Against Cymbalta Generics
Eli Lilly and Co. is pushing ahead in its effort to stop generic-drug companies from marketing copycat versions of its blockbuster antidepressant Cymbalta, filing six new lawsuits against companies including Impax...To view the full article, register now.
Already a subscriber? Click here to view full article